Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Indian Journal of Hematology and Blood Transfusion

03.06.2020 | Review Article

Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

B cell lineage acute lymphoblastic leukemia is the most common leukemia occurring in children and young adults and is the leading cause of cancer related deaths. The 5 year overall survival outcome in children with B-ALL has improved significantly in the last few decades. In the past, the discovery of various genetic alterations and targeted therapy have played a major role in decreasing disease-related deaths. In addition, numerous advances in the pathogenesis of B-ALL have been found which have provided better understanding of the genes involved in disease biology with respect to diagnostic and prognostic implications. Present review will summarize current understanding of risk stratification, genetic factors including cytogenetics in diagnosis and prognosis of B-ALL.
Literatur
1.
Mullighan CG (2012) The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2012:389–396PubMed
2.
Inaba H, Greaves M, Mullighan CG (2013) Acute lymphoblastic leukaemia. The Lancet 381(9881):1943–1955
3.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20):2375–2390PubMedPubMedCentral
4.
Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. N Engl J Med 373(16):1541–1552PubMed
5.
Secker-Walker LM, Lawler SD, Hardisty RM (1978) Prognostic implications of chromosomal findings in acute lymphoblastic leukaemia at diagnosis. Br Med J 2(6151):1529–1530PubMedPubMedCentral
6.
Dastugue N, Suciu S, Plat G, Speleman F, Cave H, Girard S et al (2013) Hyperdiploidy with 58–66 chromosomes in childhood B-acute lymphoblastic leukemia is highly curable: 58951 CLG-EORTC results. Blood 121(13):2415–2423PubMed
7.
Paulsson K, Johansson B (2009) High hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosom Cancer 48(8):637–660PubMed
8.
Carroll WL (2013) Safety in numbers: hyperdiploidy and prognosis. Blood 121(13):2374–2376PubMed
9.
Moorman AV, Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ (2010) A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood 115(2):206–214PubMed
10.
Nachman JB, Heerema NA, Sather H, Camitta B, Forestier E, Harrison CJ et al (2007) Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood 110(4):1112–1115PubMedPubMedCentral
11.
Raimondi SC, Zhou Y, Mathew S, Shurtleff SA, Sandlund JT, Rivera GK et al (2003) Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia. Cancer 98(12):2715–2722PubMed
12.
Harrison CJ, Moorman AV, Broadfield ZJ, Cheung KL, Harris RL, Reza Jalali G et al (2004) Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 125(5):552–559PubMed
13.
Safavi S, Paulsson K (2017) Near-haploid and low-hypodiploid acute lymphoblastic leukemia: two distinct subtypes with consistently poor prognosis. Blood 129(4):420–423PubMed
14.
Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L et al (2013) The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45(3):242–252PubMedPubMedCentral
15.
Pui CH, Williams DL, Raimondi SC, Rivera GK, Look AT, Dodge RK et al (1987) Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood 70(1):247–253PubMed
16.
Nowell PC (1960) A minute chromosome in human chronic granulocytic leukemia. Science 142:1497
17.
Eisenberg A, Silver R, Soper L, Arlin Z, Coleman M, Bernhardt B et al (1988) The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 2(10):642–647PubMed
18.
19.
Junmei Z, Fengkuan Y, Yongping S, Baijun F, Yuzhang L, Lina L et al (2015) Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib. SpringerPlus [Internet]. 4(1). Available from: http://​www.​springerplus.​com/​content/​4/​1/​170.​ Cited 8 Jun 2018
20.
Gupta SK, Bakhshi S, Kumar L, Kamal VK, Kumar R (2017) Gene copy number alteration profile and its clinical correlation in B cell acute lymphoblastic leukemia. Leukemia Lymphoma 58(2):333–342PubMed
21.
Singh M, Bhatia P, Trehan A, Varma N, Sachdeva MS, Bansal D et al (2018) High frequency of intermediate and poor risk copy number abnormalities in pediatric cohort of B-ALL correlate with high MRD post induction. Leuk Res 66:79–84PubMed
22.
Siddaiahgari S, Awaghad M, Latha M (2015) Clinical, immunophenotype and cytogenetic profile of acute lymphoblastic leukemia in children at tertiary health care centre in India. Muller J Med Sci Res 6(2):112
23.
Pui C-H, Robison LL, Look AT (2008) Acute lymphoblastic leukaemia. The Lancet 371(9617):1030–1043
24.
Wiemels JL, Cazzaniga G, Daniotti M, Eden OB, Addison GM, Masera G et al (1999) Prenatal origin of acute lymphoblastic leukaemia in children. Lancet 354(9189):1499–1503PubMed
25.
Pui C-H, Carroll WL, Meshinchi S, Arceci RJ (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29(5):551–565PubMed
26.
Amare PSK, Jain H, Kabre S, Deshpande Y, Pawar P, Banavali S et al (2016) Cytogenetic Profile in 7209 Indian patients with de novo acute leukemia: a single centre study from India. J. Cancer Ther 07(07):530–544
27.
Ziemin-van der Poel S, McCabe NR, Gill HJ, Espinosa R, Patel Y, Harden A et al (1991) Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias. Proc Natl Acad Sci USA 88(23):10735–10739PubMedPubMedCentral
28.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405PubMed
29.
Safavi M, Safaei A, Lotfi M (2018) A rare variant of t(17;19) in a case of Philadelphia positive adult acute lymphoblastic leukemia presenting with disseminated intravascular coagulation. Blood Res 53(1):92PubMedPubMedCentral
30.
On behalf of the Ponte di Legno International Workshop in Childhood Acute Lymphoblastic Leukemia, Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA et al (2014) An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome. Leukemia 28(5):1015–1021
31.
Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al (2010) Prognostic effect of chromosomal abnormalities in childhood B cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 11(5):429–438PubMed
32.
Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BES, Kinsey SE et al (2007) Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21). Blood 109(6):2327–2330PubMed
33.
Rand V, Parker H, Russell LJ, Schwab C, Ensor H, Irving J et al (2011) Genomic characterization implicates iAMP21 as a likely primary genetic event in childhood B cell precursor acute lymphoblastic leukemia. Blood 117(25):6848–6855PubMed
34.
Robinson HM, Harrison CJ, Moorman AV, Chudoba I, Strefford JC (2007) Intrachromosomal amplification of chromosome 21 (iAMP21) may arise from a breakage–fusion–bridge cycle. Genes Chromosom Cancer 46(4):318–326PubMed
35.
Li Y, Schwab C, Ryan SL, Papaemmanuil E, Robinson HM, Jacobs P et al (2014) Constitutional and somatic rearrangement of chromosome 21 in acute lymphoblastic leukaemia. Nature 508(7494):98–102PubMedPubMedCentral
36.
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang Y-L, Pei D et al (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371(11):1005–1015PubMedPubMedCentral
37.
38.
Roberts KG, Gu Z, Payne-Turner D, McCastlain K, Harvey RC, Chen I-M et al (2017) High frequency and poor outcome of Philadelphia chromosome-like acute lymphoblastic leukemia in adults. J Clin Oncol 35(4):394–401PubMed
39.
Reshmi SC, Harvey RC, Roberts KG, Stonerock E, Smith A, Jenkins H et al (2017) Targetable kinase gene fusions in high risk B-ALL: a study from the Children’s Oncology Group. Blood. blood-2016–12–758979.
40.
Kastner P, Dupuis A, Gaub M-P, Herbrecht R, Lutz P, Chan S (2013) Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemia. Am J Blood Res 3(1):1–13PubMedPubMedCentral
41.
Tijchon E, Havinga J, van Leeuwen FN, Scheijen B (2013) B-lineage transcription factors and cooperating gene lesions required for leukemia development. Leukemia 27(3):541–552PubMed
42.
van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, te Kronnie G, Harrison CJ et al (2014) IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 123(11):1691–1698PubMed
43.
Mi J-Q, Wang X, Yao Y, Lu H-J, Jiang X-X, Zhou J-F et al (2012) Newly diagnosed acute lymphoblastic leukemia in China (II): prognosis related to genetic abnormalities in a series of 1091 cases. Leukemia 26(7):1507–1516PubMed
44.
Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S et al (2009) Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell’Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood 114(10):2159–2167PubMed
45.
Yeoh AEJ, Lu Y, Chin WHN, Chiew EKH, Lim EH, Li Z et al (2018) Intensifying treatment of childhood B lymphoblastic leukemia with IKZF1 deletion reduces relapse and improves overall survival: results of Malaysia–Singapore ALL 2010 study. J Clin Oncol 36(26):2726–2735PubMed
46.
Harvey RC, Mullighan CG, Chen I-M, Wharton W, Mikhail FM, Carroll AJ et al (2010) Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 115(26):5312–5321PubMedPubMedCentral
47.
Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ et al (2009) Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B cell precursor acute lymphoblastic leukemia. Blood 114(13):2688–2698PubMed
48.
Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ et al (2010) Functional screening identifies CRLF2 in precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci 107(1):252–257PubMed
49.
Usvasalo A, Savola S, Räty R, Vettenranta K, Harila-Saari A, Koistinen P et al (2008) CDKN2A deletions in acute lymphoblastic leukemia of adolescents and young adults: an array CGH study. Leuk Res 32(8):1228–1235PubMed
50.
Mirebeau D, Acquaviva C, Suciu S, Bertin R, Dastugue N, Robert A et al (2006) The prognostic significance of CDKN2A, CDKN2B and MTAP inactivation in B-lineage acute lymphoblastic leukemia of childhood. Results of the EORTC studies 58881 and 58951. Haematologica 91(7):881–885PubMed
51.
Bertin R, Acquaviva C, Mirebeau D, Guidal-Giroux C, Vilmer E, Cavé H (2003) CDKN2A, CDKN2B, and MTAP gene dosage permits precise characterization of mono- and bi-allelic 9p21 deletions in childhood acute lymphoblastic leukemia: CDKN2A, CDKN2B, and MTAP Dosage in Leukemia. Genes Chromosom Cancer 37(1):44–57PubMed
52.
Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC et al (1999) Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 94(5):1537–1544PubMed
53.
Kasner MT, Wilde L, Keiffer G, Palmisiano ND, Calabretta B (2019) A phase I trial of palbociclib in combination with dexamethasone in relapsed or refractory adult B cell acute lymphoblastic leukemia (ALL). J Clin Oncol 37(15):TPS7065
54.
Zhou Y, You MJ, Young KH, Lin P, Lu G, Medeiros LJ et al (2012) Advances in the molecular pathobiology of B lymphoblastic leukemia. Hum Pathol 43(9):1347–1362PubMed
55.
Cobaleda C, Schebesta A, Delogu A, Busslinger M (2007) Pax5: the guardian of B cell identity and function. Nat Immunol 8(5):463–470PubMed
56.
Öfverholm I, Tran AN, Heyman M, Zachariadis V, Nordenskjöld M, Nordgren A et al (2013) Impact of IKZF1 deletions and PAX5 amplifications in pediatric B cell precursor ALL treated according to NOPHO protocols. Leukemia 27(9):1936–1939PubMed
57.
Sherr CJ, McCormick F (2002) The RB and p53 pathways in cancer. Cancer Cell 2(2):103–112PubMed
58.
Studniak E, Maloney E, Ociepa T, Urasiński T, Skonieczka K, Haus O et al (2013) Allelic loss of selected tumor suppressor genes in acute lymphoblastic leukemia in children. Pol J Pathol 2:121–128
59.
Waanders E, Scheijen B, van der Meer LT, van Reijmersdal SV, van Emst L, Kroeze Y et al (2012) The origin and nature of tightly clustered BTG1 deletions in precursor B cell acute lymphoblastic leukemia support a model of multiclonal evolution. PLoS Genet 8(2):e1002533PubMedPubMedCentral
60.
Schwab C, Ryan SL, Chilton L, Elliott A, Murray J, Richardson S et al (2016) EBF1-PDGFRB fusion in pediatric B cell precursor acute lymphoblastic leukemia (BCP-ALL): genetic profile and clinical implications. Blood 127(18):2214–2218PubMed
61.
Nunez R (2001) DNA measurement and cell cycle analysis by flow cytometry. Curr Issues Mol Biol 3(3):67–70PubMed
62.
Parihar M, Singh MK, Islam R, Saha D, Mishra DK, Saha V et al (2018) A triple-probe FISH screening strategy for risk-stratified therapy of acute lymphoblastic leukaemia in low-resource settings. Pediatr Blood Cancer 65(12):e27366PubMedPubMedCentral
63.
64.
Brüggemann M, Kotrova M (2017) Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation. Blood Adv 1(25):2456–2466PubMedPubMedCentral
65.
Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7(6):e577PubMedPubMedCentral
66.
Mathisen MS, O’Brien S, Thomas D, Cortes J, Kantarjian H, Ravandi F (2011) Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep 6(3):187–194PubMedPubMedCentral
67.
Leoni V, Biondi A (2015) Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica 100(3):295–299PubMedPubMedCentral
68.
Giles FJ, Swords RT, Nagler A, Hochhaus A, Ottmann OG, Rizzieri DA et al (2013) MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia. Leukemia 27(1):113–117PubMed
69.
Chiarini F, Lonetti A, Evangelisti C, Buontempo F, Orsini E, Evangelisti C et al (2016) Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: from biology to therapeutic targeting. Biochim Biophys Acta (BBA) Mol Cell Res 1863(3):449–463
70.
71.
Lionel D, Christophe L, Marc A, Jean-Luc C (2006) Oral mucositis induced by anticancer treatments: physiopathology and treatments. Ther Clin Risk Manag 2(2):159–168PubMedPubMedCentral
72.
Du X-L, Chen Q (2013) Recent advancements of bortezomib in acute lymphocytic leukemia treatment. Acta Haematol 129(4):207–214PubMed
73.
Takahashi K, Inukai T, Imamura T, Yano M, Tomoyasu C, Lucas DM et al (2017) Anti-leukemic activity of bortezomib and carfilzomib on B cell precursor ALL cell lines. PLoS ONE 12(12):e0188680PubMedPubMedCentral
74.
75.
Harrison C, Vannucchi AM (2012) Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. Ther Adv Hematol 3(6):341–354PubMedPubMedCentral
76.
Novel HD, Leukemia A-B (2011) Hematology 2011(1):243–249
77.
Levato L, Molica S (2018) Rituximab in the management of acute lymphoblastic leukemia. Expert Opin Biol Ther 18(2):221–226PubMed
78.
Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM et al (2015) Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children’s Oncology Group (COG) study ADVL04P2: re-Induction With Epratuzumab in Relapsed ALL. Pediatr Blood Cancer 62(7):1171–1175PubMedPubMedCentral
79.
Hathaway L, Sen JM, Keng M (2018) Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date. Patient Relat Outcome Measures 9:329–337
80.
Mummery A, Narendran A, Lee K-Y (2011) Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets 11(7):882–893PubMedPubMedCentral
81.
Masetti R, Serravalle S, Biagi C, Pession A (2011) The role of HDACs inhibitors in childhood and adolescence acute leukemias. J Biomed Biotechnol 2011:1–9
82.
Jing B, Jin J, Xiang R, Liu M, Yang L, Tong Y, et al (2018) Vorinostat and quinacrine have synergistic effects in T cell acute lymphoblastic leukemia through reactive oxygen species increase and mitophagy inhibition. Cell Death Disease [Internet]. 9(6). Available from: https://​www.​nature.​com/​articles/​s41419-018-0679-6. Cited 17 Dec 2019
83.
Ravandi F, Gandhi V (2006) Novel purine nucleoside analogues for T cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs 15(12):1601–1613PubMed
84.
Robak P, Robak T (2013) Older and new purine nucleoside analogs for patients with acute leukemias. Cancer Treat Rev 39(8):851–861PubMed
85.
Bonate PL, Arthaud L, Cantrell WR, Stephenson K, Secrist JA, Weitman S (2006) Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5(10):855–863PubMed
86.
Kadia TM, Gandhi V (2017) Nelarabine in the treatment of pediatric and adult patients with T cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol 10(1):1–8PubMed
87.
Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L (2013) γ-Secretase inhibitors and modulators. Biochim Biophys Acta (BBA) Biomembr 1828(12):2898–2907
88.
Greene LM, Nathwani SM, Zisterer DM (2016) Inhibition of γ-secretase activity synergistically enhances tumour necrosis factor-related apoptosis-inducing ligand induced apoptosis in T cell acute lymphoblastic leukemia cells via upregulation of death receptor 5. Oncol Lett 12(4):2900–2905PubMedPubMedCentral
89.
Evangelisti C, Evangelisti C, Chiarini F, Lonetti A, Buontempo F, Bressanin D et al (2014) Therapeutic potential of targeting mTOR in T cell acute lymphoblastic leukemia (Review). Int J Oncol 45(3):909–918PubMed
Metadaten
Titel
Recent Advances in Molecular Diagnosis and Prognosis of Childhood B Cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Publikationsdatum
03.06.2020
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2021
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-020-01295-8

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise